Diabetic Gastroparesis - Pipeline Review, H2 2016

Choose Licence

 

Diabetic Gastroparesis - Pipeline Review, H2 2016 Summary Global Markets Directs, Diabetic Gastroparesis - Pipeline Review, H2 2016?, provides an overview of the Diabetic Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis - The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects - The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Gastroparesis Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Gastroparesis - Overview 8 Pipeline Products for Diabetic Gastroparesis - Comparative Analysis 9 Diabetic Gastroparesis - Therapeutics under Development by Companies 10 Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes 11 Diabetic Gastroparesis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Diabetic Gastroparesis - Products under Development by Companies 15 Diabetic Gastroparesis - Products under Investigation by Universities/Institutes 16 Diabetic Gastroparesis - Companies Involved in Therapeutics Development 17 Cempra Inc 17 Evoke Pharma, Inc. 18 GlaxoSmithKline Plc 19 Motus Therapeutics Inc 20 Shire Plc 21 Theravance Biopharma, Inc. 22 Diabetic Gastroparesis - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 camicinal - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CEM-031 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 ETX-101 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ETX-301 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 metoclopramide hydrochloride - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 prucalopride succinate - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 relamorelin - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 velusetrag hydrochloride - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Diabetic Gastroparesis - Dormant Projects 52 Diabetic Gastroparesis - Discontinued Products 53 Diabetic Gastroparesis - Product Development Milestones 54 Featured News & Press Releases 54 Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 54 Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial 54 Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement 55 Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 55 May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 56 May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 56 May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 57 Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 57 Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 58 Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 58 Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 59 Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 59 Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 60 Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 60 Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63

List of Tables Number of Products under Development for Diabetic Gastroparesis, H2 2016 8 Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2016 17 Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2016 18 Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2016 19 Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H2 2016 20 Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2016 21 Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Diabetic Gastroparesis - Dormant Projects, H2 2016 52 Diabetic Gastroparesis - Discontinued Products, H2 2016 53


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports